Immutep Limited (PRRUF)
PRRUF Stock Price Chart
Explore Immutep Limited interactive price chart. Choose custom timeframes to analyze PRRUF price movements and trends.
PRRUF Company Profile
Discover essential business fundamentals and corporate details for Immutep Limited (PRRUF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Feb 2012
Employees
—
Website
https://www.immutep.comCEO
Marc Voigt
Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
PRRUF Financial Timeline
Browse a chronological timeline of Immutep Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 24 Feb 2026
Earnings released on 29 Jul 2025
Earnings released on 26 Feb 2025
EPS came in at -$0.01 surpassing the estimated -$0.01 by +28.35%, while revenue for the quarter reached $4.50M , beating expectations by +546.76%.
Earnings released on 29 Aug 2024
EPS came in at -$0.01 surpassing the estimated -$0.01 by +6.06%, while revenue for the quarter reached $1.15M , missing expectations by -35.74%.
Earnings released on 29 Apr 2024
EPS came in at -$0.01 surpassing the estimated -$0.01 by +10.53%, while revenue for the quarter reached $1.44M , missing expectations by -23.24%.
Earnings released on 30 Jun 2023
EPS came in at -$0.01 falling short of the estimated -$0.01 by -0.14%, while revenue for the quarter reached $1.21M , missing expectations by -43.77%.
Stock split effective on 6 Jun 2023
Shares were split 203 : 200 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Dec 2022
EPS came in at -$0.02 falling short of the estimated -$0.01 by -24.54%, while revenue for the quarter reached $1.15M .
Earnings released on 30 Jun 2022
EPS came in at -$0.01 surpassing the estimated -$0.01 by +13.67%, while revenue for the quarter reached $117.14K , missing expectations by -87.97%.
Earnings released on 31 Dec 2021
EPS came in at -$0.01 falling short of the estimated -$0.01 by -84.66%, while revenue for the quarter reached $1.51M , beating expectations by +940.34%.
Earnings released on 30 Jun 2021
EPS came in at -$0.01 surpassing the estimated -$0.02 by +48.43%, while revenue for the quarter reached $1.24M , missing expectations by -36.53%.
Earnings released on 31 Dec 2020
EPS came in at -$0.03 falling short of the estimated -$0.02 by -21.19%, while revenue for the quarter reached $1.70M , missing expectations by -0.05%.
PRRUF Stock Performance
Access detailed PRRUF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.